Amgen has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol.» Read More
Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.
The Nasdaq composite, which lost its cachet as a benchmark after the dot-com bubble burst in 2000, is back on top. Can it keep going?
Mad Money host Jim Cramer explains why he likes Celgene's acquisition of Receptos, and the lesson for investors on smart speculation.
CNBC's Meg Tirrell reports investors like the Celgene-Receptos deal, and it is putting pressure on other biotech companies to merge.
CNBC's Meg Tirrell and Robert Hugin, Celgene chairman & CEO, discuss the drugmaker's $7.3 billion bid for Receptos in an effort to acquire a third autoimmune drug.
The 21st Century Cures Act passed House 344-77 today, reports CNBC's Meg Tirrell.
Earnings labels on over the counter pain drugs like Aleve, Advil, and Motrin will now contain stronger language about the risks of heart attack and stroke, reports CNBC's Meg Tirrell.
Researchers have raised a genetically engineered crop on land that contains certain nutrients found only in fish oil and algae.
Horizon Pharma said it offered to buy Depomed for about $3 billion, taking its bid hostile after the smaller drugmaker rejected the first proposal.
As sports grapples with the effects of injuries, one area of medicine is looking to make pain and recovery a thing of the past.
The FDA approved the use of Vertex Pharmaceuticals' Orkambi, a drug aimed to treat patients with cystic fibrosis.
The actor denounced new vaccination rules in California, but insists he is not anti-vaccine.
Hans Bishop, Juno Therapeutics CEO, discusses the company's strategic collaboration with Celgene to develop advance immunotherapies for patients with cancer and autoimmune diseases.
Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.
Chart analyst John Kosar explains how to trade two stocks, he believes, are at key inflection points.
Options expert Dan Nathan explains how one trader made $144,000 on Zoetis deal chatter in a matter of minutes.
Jim Cramer says Finish Line posted a winning quarter and Alder Biopharma will determine the face of biotech.
Arie Belldegrun, Kite Pharma CEO, discusses the future of immunotherapy and its collaboration to develop cancer T-cell therapies.
CNBC's Meg Tirrell takes a look at what's driving shares of Kite Pharma higher, as the biotech company announces it is joining forces with Bluebird to collaborate on cancer T-cell therapies.
Automatic generic-drug substitution poses several big problems, says NYU Professor Melissa Schilling.
Get the best of CNBC in your inbox